Zealand Pharma A/S (OTCMKTS:ZLDPF) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Zealand Pharma A/S (OTCMKTS:ZLDPF) have earned an average recommendation of “Moderate Buy” from the eight ratings firms that are covering the firm, Marketbeat reports. Five research analysts have rated the stock with a hold rating and three have issued a strong buy rating on the company.

A number of equities analysts have weighed in on the company. BNP Paribas Exane lowered Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Friday, March 6th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Zealand Pharma A/S in a research note on Tuesday, December 16th. William Blair reissued a “market perform” rating on shares of Zealand Pharma A/S in a research note on Friday, March 6th. Finally, Cantor Fitzgerald reissued a “neutral” rating on shares of Zealand Pharma A/S in a research note on Friday, March 6th.

Zealand Pharma A/S Stock Performance

OTCMKTS ZLDPF opened at $48.30 on Thursday. The stock’s fifty day moving average is $53.56 and its two-hundred day moving average is $66.92. The firm has a market capitalization of $3.43 billion, a P/E ratio of 3.53 and a beta of 0.88. The company has a debt-to-equity ratio of 0.02, a quick ratio of 23.57 and a current ratio of 23.57. Zealand Pharma A/S has a fifty-two week low of $35.93 and a fifty-two week high of $83.12.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last released its quarterly earnings data on Thursday, February 19th. The company reported ($0.81) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.34) by $0.53. The company had revenue of $10.79 million for the quarter, compared to analyst estimates of $19.69 million. Zealand Pharma A/S had a return on equity of 48.10% and a net margin of 70.06%. On average, research analysts anticipate that Zealand Pharma A/S will post -2.19 earnings per share for the current year.

About Zealand Pharma A/S

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.